{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:56:17Z","timestamp":1792680977257,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg).<\/jats:p><\/jats:sec>Objective<\/jats:title>To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Weekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the percentage of weight loss. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 175 patients (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; mean [SD] BMI, 41.3 [9.1]) in the analysis at 3 months and 102 patients at 6 months. The mean (SD) weight loss after 3 months was 6.7 (4.4) kg, equivalent to a mean (SD) weight loss of 5.9% (3.7%) (P<\/jats:italic>\u2009&lt;\u2009.001), and the mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P<\/jats:italic>\u2009&lt;\u2009.001 from baseline). Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more. Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P<\/jats:italic>\u2009=\u2009.001) and 7.2% (6.3%) vs 11.8% (5.3%) at 6 months (P<\/jats:italic>\u2009=\u2009.005).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.31982","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:32:18Z","timestamp":1663601538000},"page":"e2231982","source":"Crossref","is-referenced-by-count":236,"title":["Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity"],"prefix":"10.1001","volume":"5","author":[{"given":"Wissam","family":"Ghusn","sequence":"first","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"De la Rosa","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sacoto","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizeth","family":"Cifuentes","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Campos","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzi","family":"Feris","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Daniela","family":"Hurtado","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"3","key":"zoi220917r1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity.","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi220917r2","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity.","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi220917r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017583","article-title":"Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system.","volume":"7","author":"Pantalone","year":"2017","journal-title":"BMJ Open"},{"key":"zoi220917r5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.v23.S1","article-title":"Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes.","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"zoi220917r6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline.","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"zoi220917r7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrendo.2017.122","article-title":"Current pharmacotherapy for obesity.","volume":"14","author":"Srivastava","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"zoi220917r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2022.100018","article-title":"Anti-obesity medications and investigational agents: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.","volume":"2","author":"Bays","year":"2022","journal-title":"Obesity Pillars"},{"issue":"1","key":"zoi220917r9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/osp4.v3.1","article-title":"Liraglutide for weight management: a critical review of the evidence.","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"issue":"3","key":"zoi220917r10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41366-021-01019-6","article-title":"Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.","volume":"46","author":"Calderon","year":"2022","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"zoi220917r11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jama.2021.9486","article-title":"Progress in pharmacotherapy for obesity.","volume":"326","author":"Yanovski","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi220917r12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/8755122518790925","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus.","volume":"34","author":"Miles","year":"2018","journal-title":"J Pharm Technol"},{"issue":"2","key":"zoi220917r15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"zoi220917r16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5.","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"zoi220917r17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1053\/gast.2002.35514","article-title":"AGA technical review on obesity.","volume":"123","author":"Klein","year":"2002","journal-title":"Gastroenterology"},{"issue":"11","key":"zoi220917r18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi220917r19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"zoi220917r20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"10278","key":"zoi220917r21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"zoi220917r22","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v22.11","article-title":"Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review.","volume":"22","author":"Ahmad","year":"2021","journal-title":"Obes Rev"},{"issue":"6","key":"zoi220917r23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/oby.2019.27.issue-6","article-title":"Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada.","volume":"27","author":"Wharton","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"zoi220917r24","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.v73.11","article-title":"Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study.","volume":"73","author":"Gorgojo-Mart\u00ednez","year":"2019","journal-title":"Int J Clin Pract"},{"key":"zoi220917r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis.","volume":"42","author":"Vosoughi","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"zoi220917r26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/8755122515604858","article-title":"Review of pharmacologic weight loss medications in a patient-centered medical home.","volume":"32","author":"Costello","year":"2016","journal-title":"J Pharm Technol"},{"issue":"1","key":"zoi220917r27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/phar.2018.38.issue-1","article-title":"Observational comparative effectiveness of pharmaceutical treatments for obesity within the Veterans Health Administration.","volume":"38","author":"Grabarczyk","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"2","key":"zoi220917r28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/oby.21726","article-title":"Method-of-use study of naltrexone sustained release (SR)\/bupropion SR on body weight in individuals with obesity.","volume":"25","author":"Halseth","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"zoi220917r29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2337\/diacare.10.5.563","article-title":"Type II diabetic subjects lose less weight than their overweight nondiabetic spouses.","volume":"10","author":"Wing","year":"1987","journal-title":"Diabetes Care"},{"issue":"3","key":"zoi220917r30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2337\/ds017-0025","article-title":"Why weight loss maintenance is difficult.","volume":"30","author":"Evert","year":"2017","journal-title":"Diabetes Spectr"},{"issue":"7617","key":"zoi220917r31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(69)90109-3","article-title":"Effect of caloric restriction on energy expenditure in obese patients.","volume":"2","author":"Bray","year":"1969","journal-title":"Lancet"},{"issue":"6","key":"zoi220917r32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/dom.2007.9.issue-6","article-title":"Insulin-associated weight gain in diabetes\u2014causes, effects and coping strategies.","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"zoi220917r33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/diacare.29.03.06.dc05-2004","article-title":"Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.","volume":"29","author":"Basu","year":"2006","journal-title":"Diabetes Care"},{"key":"zoi220917r34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"zoi220917r4","volume-title":"America\u2019s Obesity Crisis: The Health and Economic Costs of Excess Weight","author":"Waters","year":"2018"},{"key":"zoi220917r13","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH common drug review: pharmacoeconomic review report: semaglutide (Ozempic) (Novo Nordisk Canada Inc.). 2019. Accessed May 2, 2022. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0594-ozempic-pharmacoeconomic-review-report.pdf"},{"key":"zoi220917r14","unstructured":"U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. June 4, 2021. Accessed May 2, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796491\/ghusn_2022_oi_220917_1663080474.26893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:32:25Z","timestamp":1663601545000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31982","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}